Company intelligence / Profile preview

ACell

Columbia, Maryland, USA

Ownership: Private
Employees: ~300
Development stage: Other

Overview

ACell's UBM-based products (MatriStem, Cytal, MicroMatrix, Gentrix) are supported by 200+ preclinical and clinical publications, cleared by FDA for several indications in wound care and surgical repair; now part of Integra LifeSciences post-acquisition

Therapeutic areas: Women's HealthGastroenterologyOtherDermatology
Modalities: BiologicExtracellular matrix scaffold (ECM-derived biologics)
Industry: Surgical Medical Devices

Partnerships

Integration and partnership through acquisition by Integra LifeSciences

Beyond the preview

Go deeper on ACell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACell.

Explore the full profile